Physician profile
Michael A Bush
NPI 1144208950
$379,591.64
in general payments reported to CMS, 2019-2025
30 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157K · 2020: $73K · 2021: $30K · 2022: $65K · 2023: $573 · 2024: $27K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Travel and Lodging: $5,387 · Consulting Fee: $5,175 · Food and Beverage: $2,439 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,125.00 |
| Travel and Lodging | $5,387.14 |
| Consulting Fee | $5,175.00 |
| Food and Beverage | $2,439.49 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $275,294.42 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28,118.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $27,279.92 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $26,179.93 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $9,510.76 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $8,714.26 | 2019-2025 | |
| Grt US Holding, INC. | $2,132.07 | 2022 | |
| Abbvie INC. | $465.21 | 2019-2025 | Vraylar, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $278.72 | 2022-2025 | |
| Amgen INC. | $239.02 | 2019-2025 | Tepezza |
| Abbott Laboratories | $220.92 | 2019-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $159.62 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $153.23 | 2022-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Horizon Therapeutics Plc | $142.20 | 2019-2023 | Tepezza |
| Glaxosmithkline, LLC. | $131.04 | 2019-2025 | Arexvy, Shingrix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $90.83 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.36 | 2021 | |
| Recordati_rare_diseases_inc. | $56.58 | 2024 | Isturisa, Signifor Lar |
| Ethicon US, LLC | $51.97 | 2025 | Surgiflo Hemostatic Matrix |
| Mannkind Corporation | $47.61 | 2020-2023 | Afrezza |
| Ibsa Pharma INC. | $47.18 | 2022-2025 | Licart, Flector, Tirosint |
| Philips North America LLC | $28.26 | 2019 | |
| Vistapharm, INC. | $27.27 | 2021 | |
| Genentech USA, INC. | $23.51 | 2019 | |
| Heartflow, INC. | $23.16 | 2025 | |
| Medline Industries LP | $20.57 | 2025 | |
| Optos, INC. | $19.21 | 2021 | |
| Boston Scientific Corporation | $19.01 | 2024 | Bodyguardian |
| Valeritas, INC. | $18.71 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.